Suppr超能文献

他汀类药物再治疗意愿(来自地域和种族差异在卒中研究中的原因研究)。

Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study).

机构信息

University of Alabama at Birmingham, Birmingham, Alabama.

Temple University, Philadelphia, Pennsylvania.

出版信息

Am J Cardiol. 2018 Sep 1;122(5):768-774. doi: 10.1016/j.amjcard.2018.05.016. Epub 2018 Jun 2.

Abstract

Guidelines recommend attempting to reinitiate statins in patients who discontinue treatment. Previous experiences while taking a statin, including side effects, may reduce a patient's willingness to reinitiate treatment. We determined the percentage of adults who are willing to reinitiate statin therapy after treatment discontinuation. Factors associated with willingness to reinitiate a statin were also examined. A statin questionnaire was administered and study examination conducted in black and white US adults enrolled in the nationwide REasons for Geographic And Racial Differences in Stroke study from 2013 to 2017. In participants who self-reported ever having taken a statin (n = 7,216, mean age 72 years, 53% women, 34% black), 1,081 (15%) reported having discontinued treatment. Among those who discontinued treatment, statin side effects, perceived lack of need for a statin, and cost were reported by 66%, 31%, and 3% of participants, respectively. Overall, 37% of participants who had discontinued treatment were willing to reinitiate statin therapy. Participants who discontinued treatment due to cost (prevalence ratio [PR] 1.61; 95% confidence interval (CI) 1.01, 2.57) were more likely to report a willingness to reinitiate therapy. Participants with a low-density lipoprotein-cholesterol ≥130 mg/dl versus <100 mg/dl (PR 0.69; 95% CI 0.53, 0. 88) and who discontinued treatment due to side effects (PR 0.51; 95% CI 0.41, 0.64) were less likely to report willingness to reinitiate statin therapy. In conclusion, a substantial proportion of participants who discontinued statin therapy were willing to reinitiate treatment. Healthcare providers should discuss reinitiation of statin therapy with their patients who have discontinued treatment.

摘要

指南建议在停止治疗的患者中尝试重新开始使用他汀类药物。患者以前服用他汀类药物的经历,包括副作用,可能会降低他们重新开始治疗的意愿。我们确定了愿意在停止治疗后重新开始他汀类药物治疗的成年人的比例。还检查了与重新开始他汀类药物治疗意愿相关的因素。2013 年至 2017 年,在美国全国范围内的地理和种族差异中风研究中招募了黑人和白人美国成年人,他们接受了他汀类药物问卷调查和研究检查。在自我报告曾经服用过他汀类药物的参与者中(n=7216,平均年龄 72 岁,53%为女性,34%为黑人),有 1081 人(15%)报告停止了治疗。在停止治疗的患者中,分别有 66%、31%和 3%的患者报告了他汀类药物的副作用、认为不需要他汀类药物和费用问题。总体而言,37%的停止治疗的参与者愿意重新开始他汀类药物治疗。由于费用而停止治疗的参与者(患病率比 [PR] 1.61;95%置信区间 [CI] 1.01,2.57)更有可能报告重新开始治疗的意愿。低密度脂蛋白胆固醇≥130mg/dl 与<100mg/dl 的参与者(PR 0.69;95%CI 0.53,0.88)和因副作用而停止治疗的参与者(PR 0.51;95%CI 0.41,0.64)不太可能报告愿意重新开始他汀类药物治疗。总之,相当一部分停止他汀类药物治疗的参与者愿意重新开始治疗。医疗保健提供者应与停止治疗的患者讨论重新开始他汀类药物治疗。

相似文献

1
Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study).
Am J Cardiol. 2018 Sep 1;122(5):768-774. doi: 10.1016/j.amjcard.2018.05.016. Epub 2018 Jun 2.
4
Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry.
J Am Heart Assoc. 2019 Apr 2;8(7):e011765. doi: 10.1161/JAHA.118.011765.
8
The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy.
J Clin Lipidol. 2019 May-Jun;13(3):415-424. doi: 10.1016/j.jacl.2019.04.011. Epub 2019 May 18.
9
Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data.
Cardiovasc Drugs Ther. 2016 Oct;30(5):525-533. doi: 10.1007/s10557-016-6680-3.
10
Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.
Circ Genom Precis Med. 2018 Sep;11(9):e002228. doi: 10.1161/CIRCGEN.118.002228.

引用本文的文献

1
A Systematic Review Uncovering Modifiable Influences on Statin Adherence.
Patient Prefer Adherence. 2025 Jan 4;19:29-48. doi: 10.2147/PPA.S502645. eCollection 2025.
2
Statin-Induced Autoimmune Myopathy: A Diagnostic Challenge in Muscle Weakness.
Am J Case Rep. 2024 Sep 2;25:e944261. doi: 10.12659/AJCR.944261.
4
Prevalence of statin intolerance: a meta-analysis.
Eur Heart J. 2022 Sep 7;43(34):3213-3223. doi: 10.1093/eurheartj/ehac015.
6
Statin suppresses sirtuin 6 through miR-495, increasing FoxO1-dependent hepatic gluconeogenesis.
Theranostics. 2020 Sep 15;10(25):11416-11427. doi: 10.7150/thno.49770. eCollection 2020.
7
Neighborhood Participation Is Less Likely among Older Adults with Sidewalk Problems.
J Aging Health. 2021 Jan;33(1-2):101-113. doi: 10.1177/0898264320960966. Epub 2020 Sep 22.
9
A Mechanism for Statin-Induced Susceptibility to Myopathy.
JACC Basic Transl Sci. 2019 Aug 26;4(4):509-523. doi: 10.1016/j.jacbts.2019.03.012. eCollection 2019 Aug.

本文引用的文献

1
Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
J Am Coll Cardiol. 2017 Sep 5;70(10):1290-1301. doi: 10.1016/j.jacc.2017.07.752.
2
Primary Care Physician Perspectives on Barriers to Statin Treatment.
Cardiovasc Drugs Ther. 2017 Jun;31(3):303-309. doi: 10.1007/s10557-017-6738-x.
3
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27.
4
Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).
Can J Cardiol. 2016 Jul;32(7 Suppl):S35-65. doi: 10.1016/j.cjca.2016.01.003. Epub 2016 Jan 14.
6
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
Expert Opin Drug Saf. 2015 Jun;14(6):935-55. doi: 10.1517/14740338.2015.1039980. Epub 2015 Apr 24.
7
National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.
J Clin Lipidol. 2014 Sep-Oct;8(5):473-88. doi: 10.1016/j.jacl.2014.07.007. Epub 2014 Jul 15.
8
Geographic variation in medication adherence in commercial and Medicare part D populations.
J Manag Care Spec Pharm. 2014 Aug;20(8):834-42. doi: 10.18553/jmcp.2014.20.8.834.
9
An assessment by the Statin Intolerance Panel: 2014 update.
J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S72-81. doi: 10.1016/j.jacl.2014.03.002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验